Loading
The immunologist who ran the Parker Institute from its launch in 2016, building a shared research network across leading US cancer centres; he came from UCSF and now leads a regulatory T cell company.
Jeffrey Bluestone is a T cell immunologist whose laboratory work on CTLA-4 and on regulatory T cells underpins both checkpoint immunotherapy and cell therapies for autoimmunity. He was the Parker Institute for Cancer Immunotherapy's founding President and Chief Executive Officer from its public launch in 2016, and remains on its board, which lists him as Chief Executive Officer and President of Sonoma BioTherapeutics. His UCSF profile records him as the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Professor Emeritus in the Diabetes Center. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells | Journal of Experimental Medicine | 2006 |
| Innate immunity and intestinal microbiota in the development of Type 1 diabetes | Nature | 2008 |
| Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | Nature Immunology | 2009 |
These papers come from a Europe PMC search on the author's name and institution, taking the most cited articles.
Shares Parker Institute for Cancer Immunotherapy and the tags leadership, immunotherapy.
Shares the tags leadership, immunotherapy.
Shares the tags leadership, immunotherapy.
Shares CTLA-4, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Parker Institute for Cancer Immunotherapy, CTLA-4, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Parker Institute for Cancer Immunotherapy, CTLA-4, Immune checkpoint inhibitors.
Shares CTLA-4, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Immune checkpoint inhibitors and the tag immunotherapy.